rs575862721

Variant summary

Our verdict is Benign. The variant received -11 ACMG points: 0P and 11B. BP4_ModerateBP6BS1BS2

The NM_014159.7(SETD2):​c.1833G>T​(p.Lys611Asn) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000719 in 1,613,124 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Synonymous variant affecting the same amino acid position (i.e. K611K) has been classified as Likely benign.

Frequency

Genomes: 𝑓 0.000066 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000073 ( 0 hom. )

Consequence

SETD2
NM_014159.7 missense

Scores

6
12

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:3B:1

Conservation

PhyloP100: 1.68

Publications

5 publications found
Variant links:
Genes affected
SETD2 (HGNC:18420): (SET domain containing 2, histone lysine methyltransferase) Huntington's disease (HD), a neurodegenerative disorder characterized by loss of striatal neurons, is caused by an expansion of a polyglutamine tract in the HD protein huntingtin. This gene encodes a protein belonging to a class of huntingtin interacting proteins characterized by WW motifs. This protein is a histone methyltransferase that is specific for lysine-36 of histone H3, and methylation of this residue is associated with active chromatin. This protein also contains a novel transcriptional activation domain and has been found associated with hyperphosphorylated RNA polymerase II. [provided by RefSeq, Aug 2008]
SETD2 Gene-Disease associations (from GenCC):
  • Luscan-Lumish syndrome
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: G2P, Labcorp Genetics (formerly Invitae), Ambry Genetics
  • SETD2-related neurodevelopmental disorder without or with macrocephaly/overgrowth
    Inheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
  • Rabin-Pappas syndrome
    Inheritance: AD Classification: STRONG, MODERATE Submitted by: Labcorp Genetics (formerly Invitae), G2P, Ambry Genetics
  • SETD2-related microcephaly-severe intellectual disability-multiple congenital anomalies syndrome
    Inheritance: AD Classification: STRONG Submitted by: ClinGen
  • Sotos syndrome
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • intellectual developmental disorder, autosomal dominant 70
    Inheritance: AD Classification: LIMITED Submitted by: Ambry Genetics

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -11 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.15597707).
BP6
Variant 3-47122803-C-A is Benign according to our data. Variant chr3-47122803-C-A is described in ClinVar as Conflicting_classifications_of_pathogenicity. ClinVar VariationId is 582290.
BS1
Variant frequency is greater than expected in population sas. GnomAd4 allele frequency = 0.0000657 (10/152192) while in subpopulation SAS AF = 0.000207 (1/4832). AF 95% confidence interval is 0.0000476. There are 0 homozygotes in GnomAd4. There are 6 alleles in the male GnomAd4 subpopulation. Median coverage is 32. This position passed quality control check.
BS2
High AC in GnomAd4 at 10 AD gene.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
SETD2NM_014159.7 linkc.1833G>T p.Lys611Asn missense_variant Exon 3 of 21 ENST00000409792.4 NP_054878.5

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
SETD2ENST00000409792.4 linkc.1833G>T p.Lys611Asn missense_variant Exon 3 of 21 5 NM_014159.7 ENSP00000386759.3

Frequencies

GnomAD3 genomes
AF:
0.0000657
AC:
10
AN:
152192
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0000483
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.000207
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.000103
Gnomad OTH
AF:
0.00
GnomAD2 exomes
AF:
0.0000444
AC:
11
AN:
247910
AF XY:
0.0000371
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.000100
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.0000893
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.0000726
AC:
106
AN:
1460932
Hom.:
0
Cov.:
33
AF XY:
0.0000771
AC XY:
56
AN XY:
726752
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
33422
American (AMR)
AF:
0.0000225
AC:
1
AN:
44534
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
26118
East Asian (EAS)
AF:
0.00
AC:
0
AN:
39668
South Asian (SAS)
AF:
0.0000116
AC:
1
AN:
86102
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
53240
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
5758
European-Non Finnish (NFE)
AF:
0.0000917
AC:
102
AN:
1111752
Other (OTH)
AF:
0.0000331
AC:
2
AN:
60338
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.472
Heterozygous variant carriers
0
6
12
19
25
31
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
4
8
12
16
20
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0000657
AC:
10
AN:
152192
Hom.:
0
Cov.:
32
AF XY:
0.0000807
AC XY:
6
AN XY:
74358
show subpopulations
African (AFR)
AF:
0.0000483
AC:
2
AN:
41444
American (AMR)
AF:
0.00
AC:
0
AN:
15282
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3466
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5202
South Asian (SAS)
AF:
0.000207
AC:
1
AN:
4832
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10618
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
316
European-Non Finnish (NFE)
AF:
0.000103
AC:
7
AN:
68028
Other (OTH)
AF:
0.00
AC:
0
AN:
2092
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.495
Heterozygous variant carriers
0
1
2
2
3
4
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.0000332
Hom.:
0
Bravo
AF:
0.0000302
TwinsUK
AF:
0.000270
AC:
1
ALSPAC
AF:
0.00
AC:
0
ExAC
AF:
0.0000330
AC:
4
EpiCase
AF:
0.000382
EpiControl
AF:
0.000178

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:3Benign:1
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

Luscan-Lumish syndrome Uncertain:3
Apr 18, 2020
New York Genome Center
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The p.Lys611Asn variant identified in SETD2 has not been reported in affected individuals in the literature. The variant has 0.000043 allele frequency in gnomAD database (12 out of 279,304 heterozygous alleles) indicating it is a rare allele in general population. The variant affects a moderately conserved residue andin silico prediction tools show conflicting interpretations about pathogenicity of this variant. Based on the current evidence, the p.Lys611Asn variant in the SETD2 gene is assessed as a variant of uncertain significance.

Mar 15, 2022
Genome-Nilou Lab
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Aug 02, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This sequence change replaces lysine, which is basic and polar, with asparagine, which is neutral and polar, at codon 611 of the SETD2 protein (p.Lys611Asn). This variant is present in population databases (rs575862721, gnomAD 0.008%). This missense change has been observed in individual(s) with autism spectrum disorder (PMID: 25574603). ClinVar contains an entry for this variant (Variation ID: 582290). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt SETD2 protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.

not provided Benign:1
Sep 01, 2024
CeGaT Center for Human Genetics Tuebingen
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

SETD2: BS2

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.25
BayesDel_addAF
Benign
-0.17
T
BayesDel_noAF
Benign
-0.29
CADD
Benign
22
DANN
Uncertain
1.0
DEOGEN2
Benign
0.20
T;T
Eigen
Benign
0.11
Eigen_PC
Benign
0.15
FATHMM_MKL
Uncertain
0.93
D
LIST_S2
Benign
0.79
T;T
M_CAP
Uncertain
0.091
D
MetaRNN
Benign
0.16
T;T
MetaSVM
Uncertain
0.34
D
MutationAssessor
Benign
0.81
L;.
PhyloP100
1.7
PrimateAI
Uncertain
0.49
T
PROVEAN
Benign
-1.2
N;D
REVEL
Benign
0.18
Sift
Uncertain
0.0010
D;D
Sift4G
Benign
0.12
T;.
Vest4
0.25
ClinPred
0.15
T
GERP RS
3.5
PromoterAI
0.011
Neutral
Varity_R
0.36
gMVP
0.24
Mutation Taster
=87/13
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs575862721; hg19: chr3-47164293; API